ClinicalTrials.gg
RecruitingNCT07335965BORRECURUpdated Jan 13, 2026

Study of the Clinical, Microbiological and Epidemiological Characteristics of Recurrent Imported Borreliosis Confirmed by the CNR Borrelia

An observational study in Borrelia Recurrentis Infection, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
25
Ages
1 Year and older
Sex
All
01

Study summary

Recurrent borreliosis (RB) is a bacterial infection transmitted by ticks or lice. These infections occur in both temperate and tropical regions, but are rare in Australia and Antarctica. Due to climate change, the areas inhabited by the vectors of these infections are shifting, and the number of at-risk regions has significantly increased in recent years. More than twenty RB species have been described, responsible for variable clinical manifestations including fever, myalgia, digestive disorders, and sometimes neurological symptoms. Tick-borne RB represents a major public health problem, particularly in Africa. Mortality from these infections ranges from 5% to 10%. In recent years, diagnostic techniques have evolved. Microscopic diagnosis was initially the gold standard but had only moderate sensitivity and exhibited inter-operator variability. The advent of molecular biology now allows for increased sensitivity with excellent specificity and also enables the identification of the causative species.

A few cases have been described in France, consisting mainly of case reports. Therefore, this study will provide a comparative description, within a series, of cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, management, and patient outcomes.

02

Conditions studied

  • Borrelia Recurrentis Infection

Keywords

  • Borrelia Infections
  • Borrelia Recurrentis Infection
03

In context

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Minor or adult subject having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minor or adult subject
  • Having presented (from January 1, 2013, to January 1, 2025) with recurrent imported borreliosis, the diagnosis of which was confirmed by the CNR Borrelia in Strasbourg

Exclusion criteria

Exclusion Criteria:

- Refusal to participate in the study

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
25 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Clinical and biological description of cases of recurrent imported borreliosis

    This study does not include any evaluation, but simply describes cases diagnosed in France: symptoms, patients' countries of origin, Borrelia species, diagnostic techniques, and treatment.

    Time frame: Up to 12 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Oct 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2026
First posted
Jan 13, 2026
StartActual
Feb 19, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 19, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07335965
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Feb 19, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 19, 2026 (estimated)
Last update
Jan 13, 2026

Study contacts

Émilie TALAGRAND-REBOUL, MD
Contact
emilie.talagrandreboul@chru-strasbourg.fr
33 3 69 55 14 57

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion